Feasibility of Obtaining and Characterizing Circulating Tumorigenic Cells in Patients With Pancreatic Adenocarcinoma

CompletedOBSERVATIONAL
Enrollment

83

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

October 31, 2019

Study Completion Date

October 31, 2019

Conditions
Pancreatic Adenocarcinoma
Interventions
OTHER

Blood draw

Patients with pancreatic adenocarcinoma will be enrolled. Venous blood is collected in a standard 10 ml heparin blood collection tube. We may ask for blood samples at different times during the course of the study, specifically, before you start treatment and when your treatment changes. During the one year of the study, the physician anticipates blood samples will be collected a minimum of one and a maximum of four times. The amount of blood collected at any of these times will be 10 mL, about 1 tablespoon.

Trial Locations (5)

10065

Memorial Sloan Kettering Cancer Center, New York

10591

Memoral Sloan Kettering Cancer Center at Phelps, Sleepy Hollow

10604

Memorial Sloan Kettering West Harrison, Harrison

11725

Memorial Sloan Kettering Cancer Center @ Suffolk, Commack

Unknown

Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Adera Labs, LLC

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER